Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys

M. C H Ko, K. J. Willmont, A. Burritt, Victor J Hruby, J. H. Woods

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Although dynorphin A-(1-17) has been characterized in vitro as a high efficacy κ-opioid receptor agonist, functional studies of dynorphin A-(1-17) following central or systemic administration indicate the involvement of both opioid and non-opioid components. The aim of this study was to investigate whether local administration of dynorphin-related analogs can attenuate capsaicin (8-methyl-N-vanillyl-6-nonenamide)-induced nociception and what type of opioid receptor mediates the local action of dynorphin A-(1-17) in monkeys. Capsaicin (100 μg) was used to evoke a nociceptive response, thermal allodynia, which was manifested as a reduced tail-withdrawal latency in normally innocuous 46°C warm water. Co-administration of dynorphin A-(1- 17) (0.3-10 μg) with capsaicin in the tail dose-dependently inhibited thermal allodynia; however, both non-opioid fragments dynorphin A-(2-17) (10- 300 μg) and dynorphin A-(2-13) (10-300 μg) were ineffective. Local antiallodynia of dynorphin A-(1-17) was antagonized by a small dose (100 μg) of an opioid receptor antagonist, quadazocine, applied s.c. in the tail. Pretreatment with a selective κ-opioid receptor antagonist, nor- binaltorphimine (nor-BNI), s.c. 320 μg in the tail also reversed local antiallodynia of dynorphin A-(1-17). Both locally effective doses of antagonists, when applied s.c. in the back, did not antagonize local dynorphin A-(1-17), indicating that peripheral κ-opioid receptors selectively mediated the local action of dynorphin A-(1-17) in the tail. In addition, a much larger dose of dynorphin A-(1-17) (1000 μg), when administered s.c. in the back or i.m. in the thigh, did not cause sedative or diuretic effects. These results suggest that in vivo opioid actions of dynorphin-related peptides can be differentiated locally in this procedure. They also indicate that local application of peptidic ligands may be a useful medication for localized pain. (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalEuropean Journal of Pharmacology
Volume402
Issue number1-2
DOIs
StatePublished - Aug 18 2000

Fingerprint

Dynorphins
Capsaicin
Hyperalgesia
Macaca mulatta
Tail
Opioid Receptors
Narcotic Antagonists
Opioid Analgesics
Nociception
Thigh
Hypnotics and Sedatives
Diuretics
Haplorhini

Keywords

  • κ-Opioid receptors
  • Allodynia
  • Antinociception
  • Diuresis
  • Dynorphin
  • Sedation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys. / Ko, M. C H; Willmont, K. J.; Burritt, A.; Hruby, Victor J; Woods, J. H.

In: European Journal of Pharmacology, Vol. 402, No. 1-2, 18.08.2000, p. 69-76.

Research output: Contribution to journalArticle

Ko, M. C H ; Willmont, K. J. ; Burritt, A. ; Hruby, Victor J ; Woods, J. H. / Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys. In: European Journal of Pharmacology. 2000 ; Vol. 402, No. 1-2. pp. 69-76.
@article{f5a51ce79b0b47c89216f7ac66bba814,
title = "Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys",
abstract = "Although dynorphin A-(1-17) has been characterized in vitro as a high efficacy κ-opioid receptor agonist, functional studies of dynorphin A-(1-17) following central or systemic administration indicate the involvement of both opioid and non-opioid components. The aim of this study was to investigate whether local administration of dynorphin-related analogs can attenuate capsaicin (8-methyl-N-vanillyl-6-nonenamide)-induced nociception and what type of opioid receptor mediates the local action of dynorphin A-(1-17) in monkeys. Capsaicin (100 μg) was used to evoke a nociceptive response, thermal allodynia, which was manifested as a reduced tail-withdrawal latency in normally innocuous 46°C warm water. Co-administration of dynorphin A-(1- 17) (0.3-10 μg) with capsaicin in the tail dose-dependently inhibited thermal allodynia; however, both non-opioid fragments dynorphin A-(2-17) (10- 300 μg) and dynorphin A-(2-13) (10-300 μg) were ineffective. Local antiallodynia of dynorphin A-(1-17) was antagonized by a small dose (100 μg) of an opioid receptor antagonist, quadazocine, applied s.c. in the tail. Pretreatment with a selective κ-opioid receptor antagonist, nor- binaltorphimine (nor-BNI), s.c. 320 μg in the tail also reversed local antiallodynia of dynorphin A-(1-17). Both locally effective doses of antagonists, when applied s.c. in the back, did not antagonize local dynorphin A-(1-17), indicating that peripheral κ-opioid receptors selectively mediated the local action of dynorphin A-(1-17) in the tail. In addition, a much larger dose of dynorphin A-(1-17) (1000 μg), when administered s.c. in the back or i.m. in the thigh, did not cause sedative or diuretic effects. These results suggest that in vivo opioid actions of dynorphin-related peptides can be differentiated locally in this procedure. They also indicate that local application of peptidic ligands may be a useful medication for localized pain. (C) 2000 Elsevier Science B.V.",
keywords = "κ-Opioid receptors, Allodynia, Antinociception, Diuresis, Dynorphin, Sedation",
author = "Ko, {M. C H} and Willmont, {K. J.} and A. Burritt and Hruby, {Victor J} and Woods, {J. H.}",
year = "2000",
month = "8",
day = "18",
doi = "10.1016/S0014-2999(00)00503-3",
language = "English (US)",
volume = "402",
pages = "69--76",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Local inhibitory effects of dynorphin A-(1-17) on capsaicin-induced thermal allodynia in rhesus monkeys

AU - Ko, M. C H

AU - Willmont, K. J.

AU - Burritt, A.

AU - Hruby, Victor J

AU - Woods, J. H.

PY - 2000/8/18

Y1 - 2000/8/18

N2 - Although dynorphin A-(1-17) has been characterized in vitro as a high efficacy κ-opioid receptor agonist, functional studies of dynorphin A-(1-17) following central or systemic administration indicate the involvement of both opioid and non-opioid components. The aim of this study was to investigate whether local administration of dynorphin-related analogs can attenuate capsaicin (8-methyl-N-vanillyl-6-nonenamide)-induced nociception and what type of opioid receptor mediates the local action of dynorphin A-(1-17) in monkeys. Capsaicin (100 μg) was used to evoke a nociceptive response, thermal allodynia, which was manifested as a reduced tail-withdrawal latency in normally innocuous 46°C warm water. Co-administration of dynorphin A-(1- 17) (0.3-10 μg) with capsaicin in the tail dose-dependently inhibited thermal allodynia; however, both non-opioid fragments dynorphin A-(2-17) (10- 300 μg) and dynorphin A-(2-13) (10-300 μg) were ineffective. Local antiallodynia of dynorphin A-(1-17) was antagonized by a small dose (100 μg) of an opioid receptor antagonist, quadazocine, applied s.c. in the tail. Pretreatment with a selective κ-opioid receptor antagonist, nor- binaltorphimine (nor-BNI), s.c. 320 μg in the tail also reversed local antiallodynia of dynorphin A-(1-17). Both locally effective doses of antagonists, when applied s.c. in the back, did not antagonize local dynorphin A-(1-17), indicating that peripheral κ-opioid receptors selectively mediated the local action of dynorphin A-(1-17) in the tail. In addition, a much larger dose of dynorphin A-(1-17) (1000 μg), when administered s.c. in the back or i.m. in the thigh, did not cause sedative or diuretic effects. These results suggest that in vivo opioid actions of dynorphin-related peptides can be differentiated locally in this procedure. They also indicate that local application of peptidic ligands may be a useful medication for localized pain. (C) 2000 Elsevier Science B.V.

AB - Although dynorphin A-(1-17) has been characterized in vitro as a high efficacy κ-opioid receptor agonist, functional studies of dynorphin A-(1-17) following central or systemic administration indicate the involvement of both opioid and non-opioid components. The aim of this study was to investigate whether local administration of dynorphin-related analogs can attenuate capsaicin (8-methyl-N-vanillyl-6-nonenamide)-induced nociception and what type of opioid receptor mediates the local action of dynorphin A-(1-17) in monkeys. Capsaicin (100 μg) was used to evoke a nociceptive response, thermal allodynia, which was manifested as a reduced tail-withdrawal latency in normally innocuous 46°C warm water. Co-administration of dynorphin A-(1- 17) (0.3-10 μg) with capsaicin in the tail dose-dependently inhibited thermal allodynia; however, both non-opioid fragments dynorphin A-(2-17) (10- 300 μg) and dynorphin A-(2-13) (10-300 μg) were ineffective. Local antiallodynia of dynorphin A-(1-17) was antagonized by a small dose (100 μg) of an opioid receptor antagonist, quadazocine, applied s.c. in the tail. Pretreatment with a selective κ-opioid receptor antagonist, nor- binaltorphimine (nor-BNI), s.c. 320 μg in the tail also reversed local antiallodynia of dynorphin A-(1-17). Both locally effective doses of antagonists, when applied s.c. in the back, did not antagonize local dynorphin A-(1-17), indicating that peripheral κ-opioid receptors selectively mediated the local action of dynorphin A-(1-17) in the tail. In addition, a much larger dose of dynorphin A-(1-17) (1000 μg), when administered s.c. in the back or i.m. in the thigh, did not cause sedative or diuretic effects. These results suggest that in vivo opioid actions of dynorphin-related peptides can be differentiated locally in this procedure. They also indicate that local application of peptidic ligands may be a useful medication for localized pain. (C) 2000 Elsevier Science B.V.

KW - κ-Opioid receptors

KW - Allodynia

KW - Antinociception

KW - Diuresis

KW - Dynorphin

KW - Sedation

UR - http://www.scopus.com/inward/record.url?scp=0034683177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034683177&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(00)00503-3

DO - 10.1016/S0014-2999(00)00503-3

M3 - Article

VL - 402

SP - 69

EP - 76

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-2

ER -